Live Breaking News & Updates on Lyra Therapeutics Inc|Page 3
Stay updated with breaking news from Lyra therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lyra Therapeutics said Monday that the phase 3 of its Enlighten 1 trial, evaluating the company s investigational treatment LYR-210 for chronic rhinosinusitis, failed to meet its primary endpoint. ....
Less than a week ago, executives at Lyra Therapeutics Inc. were looking ahead to “imminent” data from its first phase III study in chronic rhinosinusitis (CRS), testing drug-device candidate LYR-210, a drug-device candidate largely expected to fill a much-needed gap in CRS treatment. On Monday, May 6, they were announcing plans to preserve cash in the wake of the failed Enlighten 1 study, which raised doubts as to the feasibility of the company’s CRS programs, which also include the similarly designed candidate LYR-220. ....
HC Wainwright reiterated their buy rating on shares of Lyra Therapeutics (NASDAQ:LYRA – Free Report) in a research report report published on Wednesday, Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock. A number of other research analysts have also commented on LYRA. Bank of America lowered their price target on […] ....
Research Analysts Offer Predictions for Lyra Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:LYRA) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) had its target price lowered by equities research analysts at Bank of America from $12.00 to $11.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price target would indicate a potential upside of […] ....